Neurological Disease

WMS-1410 is a selective GluN2B-containing NMDA receptor inhibitor with an IC₅₀ of 18.4 nM. WMS-1410 regulates intracellular calcium levels and protects cells from Apoptosis. WMS-1410 inhibits glutamate-induced excitotoxicity. WMS-1410 reverses NMDA/glycine-induced reduction in glucose-stimulated insulin secretion without altering physiological insulin secretion or baseline redox status, but fails to counteract insulin content loss induced by glucolipotoxicity. WMS-1410 exhibits analgesic activity against advanced neuropathic pain. WMS-1410 can be used in studies related to stroke, brain injury, Alzheimer's disease, Parkinson's disease, type 2 diabetes, and neuropathic pain.

PB-22 8-Hydroxyisoquinoline isomer is a structural isomer of PB-22. PB-22 is a cannabinoid.

Reproxalap (Standard) (ADX-102 (Standard)) is the analytical standard of Reproxalap (HY-107150). This product is intended for research and analytical applications. Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis.

Verubecestat (Standard) is the analytical standard of Verubecestat. This product is intended for research and analytical applications. Verubecestat (MK-8931) is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat effectively reduces Aβ40 and has the potential for Alzheimer's Disease.

MLKL-IN-4 (compound 56) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 82 nM. MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Org-10490 is an antagonist of dopamine D1 receptor and dopamine D2 receptor, used for the treatment for psychiatric disease.

Maprotiline-d₅ (hydrochloride) is the deuterium labeled Maprotiline hydrochloride. Maprotiline hydrochloride is a selective noradrenalin re-uptake inhibitor and a tetracyclic antidepressant.

Enolicam sodium is a dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), with a COX IC₅₀ of 1.5 μM and a 5-LOX IC₅₀ of 3.5 μM. Enolicam sodium inhibits arachidonic acid metabolism via the COX and 5-LOX pathways. Enolicam sodium inhibits the production of reactive oxygen species (ROS), superoxide anions, hydrogen peroxide, and the release of polymorphonuclear leukocytes. Enolicam sodium is applicable to research related to acute oxidative lung injury and ocular inflammation.

N-Desmethyl rosiglitazone (SB 237216) is a metabolite of Rosiglitazone (HY-17386), generated through demethylation by the cytochrome P450 enzyme system in liver microsomes. It retains partial PPARγ agonist activity and supports studies on the metabolism and pharmacokinetics of Rosiglitazone (HY-17386).

Thiethylperazine (Standard) is the analytical standard of Thiethylperazine. This product is intended for research and analytical applications. Thiethylperazine, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine has anti-emetic, antipsychotic and antimicrobial effects.

Oxidopamine hydrobromide (Standard) is the analytical standard of Oxidopamine hydrobromide (HY-B1081A). This product is intended for research and analytical applications. Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytoK_ine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of ParK_inson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.

Ubretid (Standard) is the analytical standard of Ubretid. This product is intended for research and analytical applications. Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder.

Moquizone is a choleretic agent with arrhythmia-preventing activity.

8-Br-7-CH-ADPR (8-Bromo-7-deazaadenosine-5'-O-diphosphoribose) is a specific TRPM2 antagonist that inhibits TRPM2 activation by binding to the NUDT9 homology domain of the TRPM2 channel, thereby controlling the influx of cations through the cell membrane channel. 8-Br-7-CH-ADPR can be used to study the role of TRPM2 in pathological processes such as cell death, neurodegenerative diseases, myocardial infarction, and diabetes.

Teneligliptin-d₅ (MP-513-d₅) is deuterium labeled Teneligliptin. Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC₅₀s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus.

Prindamine is a noradrenaline transporter inhibitor with very weak anticholinergic and serotonin (5-HT) uptake inhibiting effects. Prindamine blocks noradrenaline uptake, increasing synaptic availability of noradrenaline in the brain. Prindamine decreases rapid eye movement sleep (REMS) in cats. Prindamine initially increases the proportion of time spent in active wakefulness in cats.

BD-1063 is a selective σ-1 receptor antagonist with inhibitory activity against TRPC5 and TRPM3. BD-1063 exerts anti-hyperalgesic and anti-allodynic effects by inhibiting sustained calcium influx mediated by TRPC5 and TRPM3, and reverses the effects of Carrageenan (HY-125474). BD-1063 also significantly reduces excessive ethanol self-administration behavior. BD-1063 is widely used in studies on the mechanisms underlying neuropathic pain, inflammatory hyperalgesia, and alcohol abuse and dependence.

BRD5814 is a D2R antagonist. BRD5814 can be used in schizophrenia research.

Phenibut (Standard) is the analytical standard of Phenibut (HY-108403). This product is intended for research and analytical applications. Phenibut (β-Phenyl-GABA) is a GABA-B agonist. Phenibut acts as a GABA-mimetic, primarily at GABAB receptors. Phenibut has anxiolytic and nootropic (cognition enhancing) effects.

Rimtuzalcap (Standard) is the analytical standard of Rimtuzalcap (HY-109160). This product is intended for research and analytical applications. Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA).